keyword
https://read.qxmd.com/read/32227579/a-comprehensive-analysis-of-ido1-expression-with-tumour-infiltrating-immune-cells-and-mutation-burden-in-gynaecologic-and-breast-cancers
#21
Xu Feng, Ranran Tang, Runjie Zhang, Huan Wang, Zhaodong Ji, Yang Shao, Shuoer Wang, Tianying Zhong, Yun Gu, Jiao Meng
Gynaecologic and breast cancers share some similarities at the molecular level. The aims of our study are to highlight the similarities and differences about IDO1, an important immune-related gene in female cancers. The NGS data from TCGA of cervical squamous cell carcinoma (CESC), ovarian serous cystadenocarcinoma (OV), uterine corpus endometrial carcinoma (UCEC), uterine carcinosarcoma (UCS) and breast invasive carcinoma (BRCA) were analysed to identify molecular features, and clinically significant and potential therapeutic targets of IDO1...
March 30, 2020: Journal of Cellular and Molecular Medicine
https://read.qxmd.com/read/32200352/comparison-of-lymphoscintigraphy-and-single-photon-emission-computed-tomography-with-computed-tomography-spect-ct-for-sentinel-lymph-node-detection-in-endometrial-cancer
#22
Shinichi Togami, Toshihiko Kawamura, Shintaro Yanazume, Masaki Kamio, Hiroaki Kobayashi
BACKGROUND: Endometrial cancer is the most common gynecologic cancer, and lymph node metastasis is one of the most important prognostic factors. Increasing evidence shows that sentinel lymph node (SLN) mapping is an effective alternative to comprehensive lymphadenectomy. Single photon emission CT with computed tomography (SPECT/CT) is associated with a high SLN detection rate. OBJECTIVE: To compare the clinical efficacy of SPECT/CT with that of lymphoscintigraphy in detecting SLNs in patients with endometrial cancer...
March 21, 2020: International Journal of Gynecological Cancer
https://read.qxmd.com/read/32190072/the-role-of-vaginal-brachytherapy-in-stage-i-endometrial-serous-cancer-a-systematic-review
#23
REVIEW
Valentina Lancellotta, Francesca De Felice, Lisa Vicenzi, Alfredo Antonacci, Valentina Cerboneschi, Sara Costantini, Daniela di Cristino, Luca Tagliaferri, Annamaria Cerrotta, Andrea Vavassori, Sergio Gribaudo, Alessandro Colombo, Francesco Lucà, Raffaele Barbara, Monica Mangoni, Francesco Marampon, Daniela Musio, Filippo Bellati, Francesco Torcia, Vincenzo Tombolini, Mattia Falchetto Osti, Vitaliana De Sanctis
Purpose: Serous adenocarcinoma (uterine serous carcinoma - USC) is a rare and aggressive histologic subtype of endometrial cancer, with a high-rate of recurrence and poor prognosis. The adjuvant treatment for stage I patients is unclear. The purpose of this study was to evaluate the outcomes of stage I USC treated exclusively with chemotherapy plus vaginal brachytherapy (VBT). Material and methods: A systematic research using PubMed, Scopus, and Cochrane library was conducted to identify full articles evaluating the efficacy of VBT in patients with stage I USC...
February 2020: Journal of Contemporary Brachytherapy
https://read.qxmd.com/read/32183290/pathogenesis-and-clinical-management-of-uterine-serous-carcinoma
#24
REVIEW
Li Zhang, Suet Ying Kwan, Kwong Kwok Wong, Pamela T Solaman, Karen H Lu, Samuel C Mok
Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer that has not been well characterized. It accounts for less than 10% of all endometrial cancers and 80% of endometrial cancer-related deaths. Currently, staging surgery together with chemotherapy or radiotherapy, especially vaginal cuff brachytherapy, is the main treatment strategy for USC. Whole-exome sequencing combined with preclinical and clinical studies are verifying a series of effective and clinically accessible inhibitors targeting frequently altered genes, such as HER2 and PI3K3CA , in varying USC patient populations...
March 14, 2020: Cancers
https://read.qxmd.com/read/32182501/fertility-preserving-surgery-for-high-grade-epithelial-ovarian-carcinoma-confined-to-the-ovary
#25
Dimitrios Nasioudis, Spyridon A Mastroyannis, Ashley F Haggerty, Robert L Giuntoli, Mark A Morgan, Emily M Ko, Nawar A Latif
OBJECTIVE: To investigate the safety of uterine preservation in patients with high-grade epithelial ovarian carcinoma (EOC). STUDY DESIGN: The Surveillance, Epidemiology, and End Results database was accessed (1988-2014) and patients aged < = 45 years, diagnosed with an unilateral high-grade non-clear cell EOC confined to the ovary were selected. Based on surgery codes we determined whether hysterectomy was performed. Overall (OS) and cancer-specific survival (CSS) was estimated calculated following generation of Kaplan-Meier curves and compared using the log-rank test...
January 30, 2020: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://read.qxmd.com/read/32140533/selection-of-her2-neu-negative-tumor-cells-as-a-mechanism-of-resistance-to-trastuzumab-in-uterine-serous-carcinoma
#26
Silvia Pelligra, Natalia Buza, Pei Hui, Stefania Bellone, Burak Zeybek, Elena Ratner, Peter E Schwartz, Giovanni Scambia, Alessandro D Santin
Background: Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer overexpressing HER2/neu in about 30% of cases. Trastuzumab, a humanized monoclonal antibody targeting Her2/Neu, in combination with carboplatin/paclitaxel, is considered the preferred regimen for the treatment of advanced or recurrent HER2/Neu+ USC per NCCN guidelines. Case: We describe two USC patients with overexpression of HER2/neu at 2+/3+ level by immunohistochemistry and c-erbB2 gene amplification by fluorescence in situ hybridization (FISH) assay that, after an initial clinical response to trastuzumab, developed resistance/progression...
May 2020: Gynecologic Oncology Reports
https://read.qxmd.com/read/32139151/an-integrated-molecular-profile-of-endometrioid-ovarian-cancer
#27
William E Pierson, Pamela N Peters, Matthew T Chang, Lee-May Chen, David A Quigley, Alan Ashworth, Jocelyn S Chapman
OBJECTIVE: Endometrioid ovarian carcinoma (EOVC) is an uncommon subtype of epithelial ovarian carcinoma and its molecular characteristics have been incompletely described. Prior sequencing investigations have been limited to targeted gene panels. We performed whole-exome sequencing to build an unbiased genetic profile of molecular alterations in endometrioid ovarian tumors with a goal to better understand this disease in the context of epithelial ovarian cancer and endometrioid uterine cancers...
March 2, 2020: Gynecologic Oncology
https://read.qxmd.com/read/32120796/non-surgical-cancer-risk-reduction-in-brca1-mutation-carriers-disabling-the-remote-control
#28
Martin Widschwendter, Louis Dubeau
Women-specific cancers are a major health issue, particularly those associated with the BRCA 1 germline mutation carrier state, which include triple-negative basal breast carcinomas and high-grade serous ovarian carcinomas (referred to as extra-uterine Müllerian carcinomas). Whereas many chronic diseases can currently be prevented (e.g., cardiovascular diseases), no recent tangible progress was made in cancer prevention of BRCA1 mutation carriers apart from surgical resections of at-risk organs. This lack of progress is largely due to (1) poor understanding of the initiating events triggered by known risk factors in the development of these cancers, (2) the fact that current preventive measures rely on evidence obtained from adjuvant breast cancer treatment that fail to protect against poor prognostic cancers, and (3) problems with using cancer incidence in high-risk women as an ethically justifiable endpoint in cancer prevention trials...
February 27, 2020: Cancers
https://read.qxmd.com/read/32059825/european-menopause-and-andropause-society-emas-and-international-gynecologic-cancer-society-igcs-position-statement-on-managing-the-menopause-after-gynecological-cancer-focus-on-menopausal-symptoms-and-osteoporosis
#29
REVIEW
Margaret Rees, Roberto Angioli, Robert L Coleman, Rosalind Glasspool, Francesco Plotti, Tommaso Simoncini, Corrado Terranova
INTRODUCTION: Worldwide, it is estimated that about 1.3 million new gynecological cancer cases are diagnosed each year. For 2018, the predicted annual totals were cervix uteri 569,847, corpus uteri 382,069, ovary 295,414, vulva 44,235 and va​gina 17,600. Treatments include hysterectomy with or without bilateral salpingo-oophorectomy, radiotherapy and chemotherapy. These can result in loss of ovarian function and, in women under the age of 45, early menopause. AIM: The aim of this position statement is to set out an individualized approach to the management, with or without menopausal hormone therapy, of menopausal symptoms and the prevention and treatment of osteoporosis in women with gynecological cancer...
April 2020: Maturitas
https://read.qxmd.com/read/32046979/european-menopause-and-andropause-society-emas-and-international-gynecologic-cancer-society-igcs-position-statement-on-managing-the-menopause-after-gynecological-cancer-focus-on-menopausal-symptoms-and-osteoporosis
#30
Margaret Rees, Roberto Angioli, Robert L Coleman, Rosalind M Glasspool, Francesco Plotti, Tommaso Simoncini, Corrado Terranova
Worldwide, it is estimated that about 1.3 million new gynecological cancer cases are diagnosed each year. For 2018, the predicted annual totals were cervix uteri 569 847, corpus uteri 382 069, ovary 295 414, vulva 44 235, and va​gina 17 600. Treatments include hysterectomy with or without bilateral salpingo-oophorectomy, radiotherapy, and chemotherapy. These can result in loss of ovarian function and, in women under the age of 45 years, early menopause. The aim of this position statement is to set out an individualized approach to the management, with or without menopausal hormone therapy, of menopausal symptoms and the prevention and treatment of osteoporosis in women with gynecological cancer...
April 2020: International Journal of Gynecological Cancer
https://read.qxmd.com/read/31950214/adjuvant-chemotherapy-in-endometrial-cancer
#31
REVIEW
César Gómez-Raposo, María Merino Salvador, Cristina Aguayo Zamora, Enrique Casado Saenz
The role of adjuvant chemotherapy (CT) is controversial in endometrial carcinoma (EC). Surgery alone is usually curative for women who are at a low risk of disease recurrence. The treatment of EC following surgical staging is based on the risk of relapse, which is defined by the cancer stage at diagnosis, histology of the tumor and other prognostic factors such as grade differentiation, the presence of substantial lymphovascular invasion (LVSI), or depth of myometrial invasion (MI). External beam radiotherapy (EBRT) and/or vaginal brachytherapy (VBT) improved local control and are used as adjuvant treatment for early-stage disease...
March 2020: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/31906456/ubiquitin-carboxyl-terminal-hydrolase-l1-uchl1-promotes-uterine-serous-cancer-cell-proliferation-and-cell-cycle-progression
#32
Suet-Ying Kwan, Chi-Lam Au-Yeung, Tsz-Lun Yeung, Angela Rynne-Vidal, Kwong-Kwok Wong, John I Risinger, Hui-Kuan Lin, Rosemarie E Schmandt, Melinda S Yates, Samuel C Mok, Karen H Lu
Uterine serous carcinoma (USC) is the most aggressive form of endometrial cancer, with poor survival rates and high recurrence risk. Therefore, the purpose of this study was to identify therapeutic targets that could aid in the management of USC. By analyzing endometrial cancer samples from The Cancer Genome Atlas (TCGA), we found Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) to be highly expressed in USC and to correlate with poorer overall survival. UCHL1 silencing reduced cell proliferation in vitro and in vivo, cyclin B1 protein levels and cell cycle progression...
January 2, 2020: Cancers
https://read.qxmd.com/read/31890830/distant-recurrence-in-a-patient-with-polyp-confined-stage-ia-serous-endometrial-carcinoma-treated-with-adjuvant-chemotherapy-a-case-report-and-review-of-literature
#33
Annalyn Welp, Sarah Temkin, Stephanie Sullivan
Uterine serous carcinoma is a rare, high-risk histological subtype of endometrial cancer, and use of adjuvant treatment in early stage IA disease is inconsistent, especially when the tumor is confined entirely within an endometrial polyp. We herein present a case of extrauterine recurrence in a 67-year-old female with polyp-confined, stage IA uterine serous endometrial cancer. She underwent comprehensive surgical staging with the pathology returning a 5 cm uterine serous carcinoma confined completely to a 7 cm polyp with negative margins, negative myometrial and lymphovascular space invasion, and twenty-nine negative para-aortic and pelvic lymph nodes...
February 2020: Gynecologic Oncology Reports
https://read.qxmd.com/read/31883401/characteristics-and-prognostic-significance-of-incidentally-detected-cancer-cells-in-uterine-specimens-of-patients-with-pelvic-high-grade-serous-carcinoma
#34
Takeshi Ushigusa, Hiroshi Yoshida, Ikumi Kuno, Naoki Kojima, Mitsuya Ishikawa, Tomoyasu Kato
OBJECTIVE: Cases of pelvic high-grade serous carcinoma (HGSC) with incidentally detected cancer cells (ICCs) in endometrial and/or cervicovaginal cytology have been reported. This study aimed to clarify the incidence and characteristics of pelvic HGSC with ICCs and to determine whether ICCs have a negative prognostic impact. METHODS: Patients with ovarian/tubal/peritoneal HGSC who underwent pre-treatment uterine (endometrial/cervicovaginal) cytology or biopsy between January 2007 and May 2017 were included...
December 28, 2019: Cytopathology: Official Journal of the British Society for Clinical Cytology
https://read.qxmd.com/read/31867434/targeted-sequencing-of-histologically-defined-serous-endometrial-cancer-reflects-prognosis-and-correlates-with-preoperative-biopsy
#35
David Octeau, Jeremie Abitbol, Zainab Amajoud, Ido Laskov, Alex Ferenczy, Manuela Pelmus, Neta Eisenberg, Roy Kessous, Emad Matanes, Susie Lau, Amber Yasmeen, Vanessa Lopez-Ozuna, Shannon Salvador, Walter H Gotlieb, Liron Kogan
The aim of this study was to evaluate the impact of discordant endometrial sampling on the prognosis of patients finally diagnosed with uterine papillary serous carcinoma (UPSC) and to analyze UPSC mutational profile. Retrospective cohort study comparing outcomes of patients post-operatively diagnosed with UPSC and preoperatively diagnosed with endometrioid endometrial cancer (EEC) or UPSC. Genes commonly implicated in carcinogenesis were analyzed in a subgroup of 40 patients post-operatively diagnosed with UPSC, using next generation sequencing...
November 2019: Gynecologic Oncology Reports
https://read.qxmd.com/read/31866730/high-grade-endometrial-cancer-behaviour-and-outcomes-at-a-tertiary-cancer-centre
#36
Prerna Lakhwani, Priya Agarwal, Ashish Goel, Nidhi Nayar, Pankaj Pande, Kapil Kumar
High-grade endometrial carcinomas are a heterogeneous group of clinically aggressive tumours. They include FIGO grade 3 endometrioid adenocarcinoma, uterine papillary serous carcinoma (UPSC), clear cell carcinoma, undifferentiated carcinoma and carcinosarcomas or malignant mixed Mullerian tumour (MMMT). The aim of this study is to look at clinicopathological features and survival outcomes of high-grade endometrial cancers of the uterus in our centre. A tertiary care centre in India. The study design is retrospective with survival analysis...
December 2019: Indian Journal of Surgical Oncology
https://read.qxmd.com/read/31846222/a-novel-model-to-predict-cancer-specific-survival-in-patients-with-early-stage-uterine-papillary-serous-carcinoma-upsc
#37
Lihua Chen, Xiaona Liu, Mengjiao Li, Shuoer Wang, Hongyu Zhou, Lei Liu, Xi Cheng
OBJECTIVE: Stage I-II uterine papillary serous carcinoma (UPSC) has aggressive biological behavior and leads to poor prognosis. However, clinicopathologic risk factors to predict cancer-specific survival of patients with stage I-II UPSC were still unclear. This study was undertaken to develop a prediction model of survival in patients with early-stage UPSC. METHODS: Using Surveillance, Epidemiology, and End Results (SEER) database, 964 patients were identified with International Federation of Gynecology and Obstetrics (FIGO) stage I-II UPSC who underwent at least hysterectomy between 2004 and 2015...
December 17, 2019: Cancer Medicine
https://read.qxmd.com/read/31839338/in-vitro-and-in-vivo-activity-of-sacituzumab-govitecan-an-antibody-drug-conjugate-targeting-trophoblast-cell-surface-antigen-2-trop-2-in-uterine-serous-carcinoma
#38
Chanhee Han, Emanuele Perrone, Burak Zeybek, Stefania Bellone, Joan Tymon-Rosario, Gary Altwerger, Gulden Menderes, Jacqueline Feinberg, Kaitlin Haines, Mariana Espinal Muller Karger, Anna Bianchi, Luca Zammataro, Aranzazu Manzano, Elena Bonazzoli, Paola Manara, Natalia Buza, Pei Hui, Elena Ratner, Dan-Arin Silasi, Gloria S Huang, Masoud Azodi, Peter E Schwartz, Salvatore Lopez, Alessandro D Santin
OBJECTIVE: Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer with poor prognosis. Sacituzumab govitecan (SG) is a novel antibody-drug-conjugate (ADC) targeting trophoblast cell-surface antigen 2 (Trop-2), a transmembrane-calcium-signal-transducer, to deliver SN-38, the active metabolite of irinotecan. The objective of this study was to evaluate the expression of Trop-2 in USC and the preclinical activity of SG against primary USC cell-lines and xenografts. METHODS: We used immunohistochemistry (IHC) and flow-cytometry-based assays to evaluate Trop-2 expression and cell-viability in USC tissue and primary tumor-cell-lines after exposure to SG, non-targeting control ADC, and naked antibody hRS7-IgG...
November 30, 2019: Gynecologic Oncology
https://read.qxmd.com/read/31833974/targeting-human-epidermal-growth-factor-receptor-2-her2-in-gynecologic-malignancies
#39
Britt K Erickson, Burak Zeybek, Alessandro D Santin, Amanda N Fader
PURPOSE OF REVIEW: The purpose of this review is to describe the role of the human epidermal growth factor receptor 2 (HER2) as a biomarker and potential target in gynecologic malignancies and to describe contemporary updates in the use of anti-HER2 treatments for these cancers. RECENT FINDINGS: Approximately 25-30% of all patients with uterine serous carcinoma overexpress tumoral HER2. The anti-HER2 antibody trastuzumab represents an effective, targeted therapy with significant efficacy in the treatment of HER2-positive breast and gastric cancer...
December 12, 2019: Current Opinion in Obstetrics & Gynecology
https://read.qxmd.com/read/31796203/clinical-calculator-predictive-of-chemotherapy-benefit-in-stage-1a-uterine-papillary-serous-cancers
#40
D P Mysona, L K H Tran, P M H Tran, P A Gehrig, L Van Le, S Ghamande, B J Rungruang, J Java, A K Mann, J Liao, D S Kapp, Bruno Dos Santos, J X She, J K Chan
OBJECTIVE: Determine the utility of a clinical calculator to predict the benefit of chemotherapy in stage IA uterine papillary serous cancer (UPSC). PATIENTS AND METHODS: Data were collected from NCDB from years 2010-2014. Based on demographic and surgical characteristics, a clinical score was developed using the random survival forest machine learning algorithm. RESULTS: Of 1,751 patients with stage IA UPSC, 1,012 (58%) received chemotherapy and 739 (42%) did not...
January 2020: Gynecologic Oncology
keyword
keyword
16962
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"